Epigenetic variants of xenobiotic metabolism affect individual differences in antiepileptic drug 3,4-DCPB pharmacokinetic phenotype
Yingyuan Lu,Mei Zhang,Shengju Yin,Xiaona Dong,Zhiyuan Zhang,Haixu Cheng,Pengfei Tu,Guifang Dou,Yongsheng Che,Zhenghui Xu,Feng Xu,Xian Wang,Chuang Lu,Yaqing Lou,Guoliang Zhang
2023-01-01
Journal of Chinese Pharmaceutical Sciences
Abstract:Antiepileptic drug therapy is a main method for controlling epilepsy,but the responses of patients to the current treatments are not consistent due to inter-individual differences in drug disposition.In the present study,we investigated whether genetic and epigenetic variants affected the pharmacokinetic phenotypes of the antiepileptic drug 3,4-dichlorophenyl-propenoyl-sec-butylamine(3,4-DCPB)in phase I dose-escalation clinical trial in healthy subjects.The plasma concentrations of 3,4-DCPB and its major metabolite Ml were determinated by the liquid chromatography tandem mass spectrometry(LC-MS/MS)method.Single nucleotide polymorphisms(SNPs)of xenobiotic metabolisms including cytochrome P450 2D6(CYP2D6),CYP2C9,CYP1A2,CYP2C19,CYP3A5,transporter ABCB1(C1236T),nuclear receptors AhR,CAR and PXR were analyzed by genotyping and DNA methylation levels for these genes.Compared to the wild-type CYP2D6*1/*1 homozygote(extensive metabolizers,EMs),the variant allelic CYP2D6*10 carriers(intermediate metabolizers,IMs)showed that the area under the curve(AUC0-t)ratios of metabolite Ml/3,4-DCPB parent drug were lower,and the plasma half-life(t1/2)ratios were prolonger,while the DNA methylation levels were higher.These data suggested that epimutation induced by lose(CYP2D6*10,C＞T)of cytosine,might explain the associations among genotype,epigenotype and individual differences in the pharmacokinetic phenotype of 3,4-DCPB,and provide new insight in personalized treatment of epilepsy.